Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients
This retrospective study aimed to evaluate whether anti-glycoproteins (GPs) autoantibodies can be used as predictors of response to high-dose dexamethasone combined with rituximab (DXM-RTX) in the treatment of primary immune thrombocytopenia (ITP) patients. One-hundred twenty-six ITP patients were i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2023.2258988 |
| _version_ | 1797638457402589184 |
|---|---|
| author | Bingjie Ding Liu Liu Mengjuan Li Xuewen Song Yuanyuan Zhang Ao Xia Jingyuan Liu Hu Zhou |
| author_facet | Bingjie Ding Liu Liu Mengjuan Li Xuewen Song Yuanyuan Zhang Ao Xia Jingyuan Liu Hu Zhou |
| author_sort | Bingjie Ding |
| collection | DOAJ |
| description | This retrospective study aimed to evaluate whether anti-glycoproteins (GPs) autoantibodies can be used as predictors of response to high-dose dexamethasone combined with rituximab (DXM-RTX) in the treatment of primary immune thrombocytopenia (ITP) patients. One-hundred twenty-six ITP patients were included and retrospectively analyzed, 66.7% of anti-GPIb/IX and 65.9% of anti-GPIIb/IIIa autoantibodies. Results showed that overall response (OR) and complete response (CR) rates of patients without anti-GPIb/IX autoantibodies to DXM-RTX were significantly higher than those with anti-GPIb/IX autoantibodies at 4 weeks (OR: 73.8% vs. 47.6%, CR: 50.0% vs. 26.2%; P < 0.05) and 6 months (OR: 71.4% vs. 45.2%, CR: 42.9% vs. 25.0%; P < .05). Furthermore, patients with anti-GPIb/IX single-positivity exhibited higher resistance to DXM-RTX than patients with anti-GPIIb/IIIa single-positivity at 4 weeks (OR: 37.5% vs. 78.3%; P < .05) and 6 months (OR: 29.2% vs. 78.3%; P < .05). Multivariable logistic regression analysis revealed that anti-GPIb/IX autoantibodies and megakaryocytes were associated with the OR rate of patients at both 4 weeks and 6 months, and anti-GPIb/IX autoantibodies at 4 weeks represented the only significant factor affecting OR rate with DXM-RTX (F = 9.128, P = .003). Therefore, platelet anti-GPIb/IX autoantibodies might predict poor response to DXM-RTX in ITP patients. |
| first_indexed | 2024-03-11T13:03:45Z |
| format | Article |
| id | doaj.art-b670116aa1104b52b83b99d8e8f0e58c |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-11T13:03:45Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-b670116aa1104b52b83b99d8e8f0e58c2023-11-03T16:27:52ZengTaylor & Francis GroupPlatelets0953-71041369-16352023-12-0134110.1080/09537104.2023.22589882258988Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patientsBingjie Ding0Liu Liu1Mengjuan Li2Xuewen Song3Yuanyuan Zhang4Ao Xia5Jingyuan Liu6Hu Zhou7The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceFirst Affiliated Hospital of Zhengzhou UniversityThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan ProvinceThis retrospective study aimed to evaluate whether anti-glycoproteins (GPs) autoantibodies can be used as predictors of response to high-dose dexamethasone combined with rituximab (DXM-RTX) in the treatment of primary immune thrombocytopenia (ITP) patients. One-hundred twenty-six ITP patients were included and retrospectively analyzed, 66.7% of anti-GPIb/IX and 65.9% of anti-GPIIb/IIIa autoantibodies. Results showed that overall response (OR) and complete response (CR) rates of patients without anti-GPIb/IX autoantibodies to DXM-RTX were significantly higher than those with anti-GPIb/IX autoantibodies at 4 weeks (OR: 73.8% vs. 47.6%, CR: 50.0% vs. 26.2%; P < 0.05) and 6 months (OR: 71.4% vs. 45.2%, CR: 42.9% vs. 25.0%; P < .05). Furthermore, patients with anti-GPIb/IX single-positivity exhibited higher resistance to DXM-RTX than patients with anti-GPIIb/IIIa single-positivity at 4 weeks (OR: 37.5% vs. 78.3%; P < .05) and 6 months (OR: 29.2% vs. 78.3%; P < .05). Multivariable logistic regression analysis revealed that anti-GPIb/IX autoantibodies and megakaryocytes were associated with the OR rate of patients at both 4 weeks and 6 months, and anti-GPIb/IX autoantibodies at 4 weeks represented the only significant factor affecting OR rate with DXM-RTX (F = 9.128, P = .003). Therefore, platelet anti-GPIb/IX autoantibodies might predict poor response to DXM-RTX in ITP patients.http://dx.doi.org/10.1080/09537104.2023.2258988primary immune thrombocytopeniadexamethasone combined with rituximab therapyanti-gpib/ix autoantibodiespredictor of response |
| spellingShingle | Bingjie Ding Liu Liu Mengjuan Li Xuewen Song Yuanyuan Zhang Ao Xia Jingyuan Liu Hu Zhou Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients Platelets primary immune thrombocytopenia dexamethasone combined with rituximab therapy anti-gpib/ix autoantibodies predictor of response |
| title | Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| title_full | Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| title_fullStr | Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| title_full_unstemmed | Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| title_short | Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| title_sort | anti gpib ix autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients |
| topic | primary immune thrombocytopenia dexamethasone combined with rituximab therapy anti-gpib/ix autoantibodies predictor of response |
| url | http://dx.doi.org/10.1080/09537104.2023.2258988 |
| work_keys_str_mv | AT bingjieding antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT liuliu antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT mengjuanli antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT xuewensong antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT yuanyuanzhang antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT aoxia antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT jingyuanliu antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients AT huzhou antigpibixautoantibodiesareassociatedwithpoorresponsetodexamethasonecombinedwithrituximabtherapyinprimaryimmunethrombocytopeniapatients |